Latest Pharma and Biotech News
Biotechnology
30 December 2024 Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, delivering targeted cancer therapy. ADCs concentrate treatment at tumor sites, enhancing efficacy while minimizing harm to healthy tissues.
Today's issue
Refine Search
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Pharmaceutical
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Pharmaceutical
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib. 2 January 2025
Pharmaceutical
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of Health and Human Services (HHS) Secretary Xavier Becerra has announced. 2 January 2025
Pharmaceutical
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), from US pharma giant Merck & Co. 31 December 2024
Pharmaceutical
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion). 31 December 2024
Pharmaceutical
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with Denmark’s Novo Nordisk continues. 31 December 2024
Pharmaceutical
The US Food and Drug Administration (FDA) is reopening the comment period for the Federal Register notice (FRN), “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments” due to high interest from industry. 31 December 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning urging the public to avoid purchasing weight-loss medicines without a prescription. 30 December 2024
Pharmaceutical
For many in the life sciences, the year gone by has been marked by volatility across a range of metrics, as political and economic disruptions threaten to upend the standard operating model. 30 December 2024
Pharmaceutical
China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases. 30 December 2024
Pharmaceutical
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the use of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) in patients with agammaglobulinemia or hypogammaglobulinemia disorders, from domestic drug giant Takeda Pharma 27 December 2024
Pharmaceutical
Japanese drugmaker Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for the global development, manufacturing and commercialization of a STAT6 program that Kaken is developing. 27 December 2024
Pharmaceutical
Akums, India’s largest contract development and manufacturing organization (CDMO), has signed a strategic agreement with an undisclosed global pharmaceutical company. 27 December 2024
All news
Pharmaceutical
Biomarker-driven clinical research and development company Precision for Medicine has announced that Harpreet Singh has joined the Maryland firm as chief medical officer. 22 May 2024
Pharmaceutical
Privately-held Swiss company Swixx Biopharma today announced a strategic acquisition of Biopas, one of Latin America’s leading marketing and distribution companies for international biopharmaceutical firms. 22 May 2024
Pharmaceutical
Rhythm Pharmaceuticals, a US biopharma specializing in rare neuroendocrine diseases, has announced that its drug Imcivree (setmelanotide) is expected to be funded and available for use in England and Wales within three months through the National Health Service (NHS) in specialist centers. 22 May 2024
Pharmaceutical
The Journal of Clinical Psychopharmacology has published a post hoc analysis of data from the Phase III KINECT-4 study of Ingrezza (valbenazine). 22 May 2024
Pharmaceutical
Taking another step into the sector, US pharma major Eli Lilly has signed an agreement with Boston, USA-based biotech firm Aktis Oncology, to generate anticancer radiopharmaceuticals using the latter’s novel miniprotein technology platform. 21 May 2024
Pharmaceutical
Foghorn Therapeutics has announced the pricing of a direct share offering, with the goal of raising $110 million. 21 May 2024
Pharmaceutical
Israeli dermatology company Sol-Gel Technologies has signed an agreement with Beimei Pharma for the commercialization of Twyneo (tretinoin/benzoyl peroxide) in China, Hong Kong, Macau, Taiwan and Israel. 21 May 2024
Pharmaceutical
While AstraZeneca’s chief executive Pascal Soriot has been proven right about many of his prior boasts on the company’s future success during his 12-year reign, his latest claim could be questioned even by his strongest supporters. 21 May 2024
Pharmaceutical
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
Pharmaceutical
Following a review of its strategic options, Swedish immunology company InDex Pharmaceuticals has opted for a reverse merger with Stockholm-based Flerie Invest. 21 May 2024
Pharmaceutical
Rapport Therapeutics, a company with a footprint in both Boston and San Diego, USA, has outlined plans for an initial public offering. 20 May 2024
Pharmaceutical
Gilead Sciences has announced positive interim results from the ongoing ASSURE study of seladelpar. 20 May 2024
Pharmaceutical
Japanese drugmaker Otsuka has announced that the primary endpoint was achieved in the Phase III trial in Japan of bempedoic acid as a potential treatment for patients with hypercholesterolemia. 20 May 2024
Pharmaceutical
Finnish pharma trade group Pharma Industry Finland (PIF) has published its annual survey into investment levels in the nation. 20 May 2024
Pharmaceutical
Ireland is attracting fewer clinical trials than some European countries with similar populations and economic performances, according to a report by the Irish Pharmaceutical Healthcare Association (IPHA), which represents the research-based biopharmaceutical industry. 20 May 2024
Pharmaceutical
Swiss cancer giant Novartis and German drugmaker Bayer are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024. 17 May 2024
Expert View
In an Expert View column, Bruce Leuchter, chief executive of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, outlines the importance of increased investment in research and development and innovative business models, to bring more therapies for neurological disorders to patients. 17 May 2024
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical has received supplemental approvals for the BRAF inhibitor Braftovi (encorafenib), and the MEK inhibitor Mektovi (binimetinib), when used in combination, in Japan for two new indications. 17 May 2024
Pharmaceutical
At its meeting this week the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) reviewed medicines regarding their safety. 17 May 2024
Pharmaceutical
German drugmaker Bayer will present positive results from the OASIS 1 and 2 studies at the annual meeting of the American College of Obstetricians and Gynecologists (ACOG) today. 17 May 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze